Tripep strengthens its patent position on hepatit C virus vaccines

Tripep announces that the company today received a US patent for the gene used in the therapeutic vaccine ChronVac-C ®

Tripep has today received a first independent US patent related to the therapeutic vaccine ChronVac-C®. In february 2005, Tripep announced that a first patent had been received covering the ChronVac-C gene and its use in vaccines in combination with ribavirin. The patent that Tripep received today covers the gene itself, and contains so called “compositions claims”, and the use of the gene for vaccine purposes. ”This is our so far most important patent concerning ChronVac-C and shows that our patent position within hepatitis C is strong. It is with confidence that we continue with the development and commercialization of ChronVac-C” says Tripep’s CEO Jan Nilsson.